{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001402453,0.0002264155,0.0004390922,0.0001128471,0.0001346135,0.00003116457,0.0000786938,0.00004226327,0.00002599958],"category_scores_gemma":[0.00001958289,0.0001167363,0.00001970056,0.0004135782,0.0001877318,0.0002029881,0.00002254287,0.0001607271,0.000002463069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000147331,"about_ca_system_score_gemma":0.0002318863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001856575,"about_ca_topic_score_gemma":0.0002852364,"domain_scores_codex":[0.9986803,0.0000946685,0.0003451528,0.0003243489,0.0003517685,0.0002037649],"domain_scores_gemma":[0.9988884,0.0001336494,0.0002902049,0.0003353069,0.0002743226,0.00007815511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01631273,0.02899815,0.9314007,0.00006812712,0.0004056098,0.00003829009,0.008857426,0.0003489198,0.001186126,0.0001395045,0.0001100164,0.01213441],"study_design_scores_gemma":[0.1621848,0.113033,0.7066556,0.0004529758,0.0004194385,0.00001026682,0.005863289,0.0001348284,0.01059737,0.00001837958,0.0002926727,0.0003373381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946492,0.0001113485,0.0000153329,0.0003672733,0.00007727388,0.004304452,0.00003705981,0.00003467387,0.0004034358],"genre_scores_gemma":[0.9987894,0.00001942171,0.0003474029,0.0001549097,0.00002990068,0.0003284491,0.0001130812,0.00003018751,0.0001872347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2247451,"threshold_uncertainty_score":0.4760368,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009872657720289805,"score_gpt":0.3163407426654571,"score_spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}